Drug Profile


Alternative Names: AVE 1625

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class Antidementias; Antipsychotics; Halogenated hydrocarbons; Obesity therapies; Small molecules; Sulfonamides
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Obesity; Parkinson's disease; Schizophrenia; Type 2 diabetes mellitus

Most Recent Events

  • 29 Jul 2009 Discontinued - Phase-II for Schizophrenia in Canada (PO)
  • 29 Jul 2009 Discontinued - Phase-II for Schizophrenia in European Union (PO)
  • 29 Jul 2009 Discontinued - Phase-II for Schizophrenia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top